Literature DB >> 18243251

Genes encoded within 8q24 on the amplicon of a large extrachromosomal element are selectively repressed during the terminal differentiation of HL-60 cells.

Tetsuo Hirano1, Fumio Ike, Takehide Murata, Yuichi Obata, Hiroyasu Utiyama, Kazunari K Yokoyama.   

Abstract

Human acute myeloblastic leukemia HL-60 cells become resistant to differentiation during long-term cultivation. After 150 passages, double minute chromosomes (dmins) found in early-passaged cells are replaced by large extrachromosomal elements (LEEs). In a DNA library derived from a purified fraction of LEEs, 12.6% (23/183) of clones were assigned to 8q24 and 9.2% (17/183) were assigned to 14q11 in the human genome. Fluorescence in situ hybridization (FISH) revealed a small aberrant chromosome, which had not been found in early-passaged cells, in addition to the purified LEEs. We determined that each LEE consisted of six discontinuous segments in a region that extended for 4.4Mb over the 8q24 locus. Five genes, namely, Myc (a proto-oncogene), NSMCE2 (for a SUMO ligase), CCDC26 (for a retinoic acid-dependent modulator of myeloid differentiation), TRIB1 (for a regulator of MAPK kinase) and LOC389637 (for a protein of unknown function), were encoded by the amplicon. Breaks in the chromosomal DNA within the amplicon were found in the NSMCE2 and CCDC26 genes. The discontinuous structure of the amplicon unit of the LEEs was identical with that of dmins in HL-60 early-passaged cells. The difference between them seemed, predominantly, to be the number (10-15 copies per LEE versus 2 or 3 copies per dmin) of constituent units. Expression of the Myc, NSMCE2, CCDC26 and LOC389637 and TRIB1 genes was constitutive in all lines of HL-60 cells and that of the first four genes was repressed during the terminal differentiation of early-passaged HL-60 cells. We also detected abnormal transcripts of CCDC26. Our results suggest that these genes were selected during the development of amplicons. They might be amplified and, sometimes, truncated to contribute to the maintenance of HL-60 cells in an undifferentiated state.

Entities:  

Mesh:

Year:  2007        PMID: 18243251     DOI: 10.1016/j.mrfmmm.2007.12.008

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  9 in total

1.  Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24.

Authors:  Stefanie Birnbaum; Kerstin U Ludwig; Heiko Reutter; Stefan Herms; Michael Steffens; Michele Rubini; Carlotta Baluardo; Melissa Ferrian; Nilma Almeida de Assis; Margrieta A Alblas; Sandra Barth; Jan Freudenberg; Carola Lauster; Gül Schmidt; Martin Scheer; Bert Braumann; Stefaan J Bergé; Rudolf H Reich; Franziska Schiefke; Alexander Hemprich; Simone Pötzsch; Regine P Steegers-Theunissen; Bernd Pötzsch; Susanne Moebus; Bernhard Horsthemke; Franz-Josef Kramer; Thomas F Wienker; Peter A Mossey; Peter Propping; Sven Cichon; Per Hoffmann; Michael Knapp; Markus M Nöthen; Elisabeth Mangold
Journal:  Nat Genet       Date:  2009-03-08       Impact factor: 38.330

2.  Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia.

Authors:  Ina Radtke; Charles G Mullighan; Masami Ishii; Xiaoping Su; Jinjun Cheng; Jing Ma; Ramapriya Ganti; Zhongling Cai; Salil Goorha; Stanley B Pounds; Xueyuan Cao; Caroline Obert; Jianling Armstrong; Jinghui Zhang; Guangchun Song; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Sheila A Shurtleff; James R Downing
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

3.  Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression.

Authors:  Tetsuo Hirano; Ryoko Yoshikawa; Hironori Harada; Yuka Harada; Atsuhiko Ishida; Takeshi Yamazaki
Journal:  Mol Cancer       Date:  2015-04-19       Impact factor: 27.401

Review 4.  Association between IRF6 and 8q24 polymorphisms and nonsyndromic cleft lip with or without cleft palate: Systematic review and meta-analysis.

Authors:  Kachin Wattanawong; Sasivimol Rattanasiri; Mark McEvoy; John Attia; Ammarin Thakkinstian
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2016-08-11

5.  Sequence variant at 8q24.21 associates with sciatica caused by lumbar disc herniation.

Authors:  Gyda Bjornsdottir; Stefania Benonisdottir; Gardar Sveinbjornsson; Unnur Styrkarsdottir; Gudmar Thorleifsson; G Bragi Walters; Aron Bjornsson; Ingvar H Olafsson; Elfar Ulfarsson; Arnor Vikingsson; Ragnheidur Hansdottir; Karl O Karlsson; Thorunn Rafnar; Ingileif Jonsdottir; Michael L Frigge; Augustine Kong; Asmundur Oddsson; Gisli Masson; Olafur T Magnusson; Tomas Gudbjartsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Unnur Thorsteinsdottir; Thorgeir E Thorgeirsson; Kari Stefansson
Journal:  Nat Commun       Date:  2017-02-22       Impact factor: 14.919

6.  Downregulation of lncRNA CCDC26 contributes to imatinib resistance in human gastrointestinal stromal tumors through IGF-1R upregulation.

Authors:  Jingyi Yan; Didi Chen; Xiaolei Chen; Xuecheng Sun; Qiantong Dong; Changyuan Hu; Feng Zhou; Wei Chen
Journal:  Braz J Med Biol Res       Date:  2019-06-03       Impact factor: 2.590

Review 7.  8q24.21 Locus: A Paradigm to Link Non-Coding RNAs, Genome Polymorphisms and Cancer.

Authors:  Claire Wilson; Aditi Kanhere
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

Review 8.  Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors.

Authors:  Xiangchen Hu; Zhe Wang; Peng Su; Qiqi Zhang; Youwei Kou
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

9.  8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia.

Authors:  Yoshiaki Chinen; Natsumi Sakamoto; Hisao Nagoshi; Tomohiko Taki; Saori Maegawa; Shotaro Tatekawa; Taku Tsukamoto; Shinsuke Mizutani; Yuji Shimura; Mio Yamamoto-Sugitani; Tsutomu Kobayashi; Yosuke Matsumoto; Shigeo Horiike; Junya Kuroda; Masafumi Taniwaki
Journal:  J Hematol Oncol       Date:  2014-09-23       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.